Macrogenics (MGNX) Income towards Parent Company (2012 - 2026)
Macrogenics' (MGNX) quarterly Income towards Parent Company came in at -$38.9 million in Q1 2026, up 8.91% year-on-year from -$35.7 million in Q1 2025, and down 175.42% on a QoQ basis from -$14.1 million in Q4 2025.
Macrogenics (MGNX) Income towards Parent Company (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Income towards Parent Company data on file, last reported at -$38.9 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 8.91% year-over-year to -$38.9 million in Q1 2026; TTM through Mar 2026 was -$72.5 million, a 26.04% decrease from a year earlier, with the FY2025 full-year figure at -$74.6 million, down 11.39% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$38.9 million, down from -$14.1 million in the prior quarter.
- Over the last five years, Income towards Parent Company for MGNX reached as high as $56.3 million in Q3 2024 and fell as low as -$100.2 million in Q1 2024.
- Historically, Income towards Parent Company has averaged -$31.2 million across 5 years, with a median of -$38.9 million in 2026.
- Across the five-year window, Income towards Parent Company slumped 511.87% in 2023 and soared 258.61% in 2024, its largest moves.
- Year by year, Income towards Parent Company stood at $12.0 million in 2022, then slumped by 511.87% to -$49.4 million in 2023, then surged by 68.75% to -$15.4 million in 2024, then grew by 8.39% to -$14.1 million in 2025, then tumbled by 175.42% to -$38.9 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were -$38.9 million in Q1 2026, -$14.1 million in Q4 2025, and $16.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Macrogenics | 230.64 Mn | 164.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.91 Mn |
| Dec 31, 2025 | -14.13 Mn |
| Sep 30, 2025 | 16.82 Mn |
| Jun 30, 2025 | -36.25 Mn |
| Mar 31, 2025 | -42.72 Mn |
| Dec 31, 2024 | -15.42 Mn |
| Sep 30, 2024 | 56.31 Mn |
| Jun 30, 2024 | -55.66 Mn |
| Mar 31, 2024 | -100.20 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -47.06 Mn |
| Mar 31, 2023 | -46.25 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -67.54 Mn |
| Dec 31, 2021 | -385.83 Mn |
| Sep 30, 2021 | -72.91 Mn |
| Jun 30, 2021 | -94.21 Mn |